Compare CVBF & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVBF | IDYA |
|---|---|---|
| Founded | 1974 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | 2009 | 2019 |
| Metric | CVBF | IDYA |
|---|---|---|
| Price | $18.88 | $33.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $24.17 | ★ $51.21 |
| AVG Volume (30 Days) | ★ 1.1M | 797.3K |
| Earning Date | 04-22-2026 | 05-19-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | 5.56 | ★ 61.90 |
| EPS | ★ 1.52 | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $21.55 | N/A |
| Revenue Next Year | $15.13 | $97.58 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $16.01 | $13.45 |
| 52 Week High | $21.48 | $39.28 |
| Indicator | CVBF | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 50.98 |
| Support Level | $18.16 | $32.85 |
| Resistance Level | $19.56 | $33.64 |
| Average True Range (ATR) | 0.55 | 1.43 |
| MACD | -0.16 | 0.30 |
| Stochastic Oscillator | 16.97 | 59.43 |
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.